Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study

Published:2018-03 Issue: Volume:66 Page:66-72
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Najima Yuho,Yoshida Chikashi,Iriyama Noriyoshi,Fujisawa Shin,Wakita Hisashi,Chiba Shigeru,Okamoto Shinichiro,Kawakami Kimihiro,Takezako Naoki,Kumagai Takashi,Ohyashiki Kazuma,Taguchi Jun,Yano Shingo,Igarashi Tadahiko,Kouzai Yasuji,Morita Satoshi,Sakamoto Junichi,Sakamaki Hisashi,Inokuchi Koiti

Funder

Novartis Pharma

Bristol-Myers Squibb and Pfizer

Otsuka Pharmaceutical

Bristol-Myers Squibb and Novartis Pharma

Pfizer

Bristol-Myers Squibb

Bristol-Myers Squibb, Novartis Pharma

non-profit organization Epidemiological and Clinical Research Information Network (ECRIN)

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Cancer immunology;Finn;N. Engl. J. Med.,2008

2. Regulatory T cells in cancer immunotherapy;Nishikawa;Curr. Opin. Immunol.,2014

3. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival;Curiel;Nat. Med.,2004

4. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions;Hiraoka;Clin. Cancer Res.,2006

5. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis;Kobayashi;Clin. Cancer Res.,2007

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial);International Journal of Hematology;2024-08-13

2. Small molecule inhibitors targeting regulatory T cells for cancer treatment;European Journal of Immunology;2023-11-15

3. Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review;Current Pharmacology Reports;2023-04-10

4. Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging;Pharmaceutics;2023-03-11

5. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome;Cells;2023-02-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3